Princeton Global Asset Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $22.5K | Sell |
933
-43
| -4% | -$1.13K | ﹤0.01% | 466 |
|
|
2026
Q1 | $27.4K | Buy |
976
+37
| +4% | +$985 | ﹤0.01% | 436 |
|
|
2025
Q4 | $23.4K | Sell |
939
-692
| -42% | -$17.5K | ﹤0.01% | 464 |
|
|
2025
Q3 | $41.6K | Buy |
1,631
+200
| +14% | +$4.94K | 0.01% | 346 |
|
|
2025
Q2 | $34.7K | Sell |
1,431
-2,332
| -62% | -$54.4K | 0.01% | 361 |
|
|
2025
Q1 | $95.4K | Buy |
3,763
+333
| +10% | +$8.71K | 0.02% | 231 |
|
|
2024
Q4 | $91K | Hold |
3,430
| – | – | 0.02% | 252 |
|
|
2024
Q3 | $99.3K | Sell |
3,430
-1,184
| -26% | -$34.5K | 0.02% | 244 |
|
|
2024
Q2 | $129K | Buy |
4,614
+271
| +6% | +$7.46K | 0.03% | 199 |
|
|
2024
Q1 | $121K | Sell |
4,343
-183
| -4% | -$5.08K | 0.03% | 189 |
|
|
2023
Q4 | $130K | Sell |
4,526
-1,144
| -20% | -$34.6K | 0.03% | 185 |
|
|
2023
Q3 | $188K | Buy |
5,670
+10
| +0.2% | +$354 | 0.05% | 161 |
|
|
2023
Q2 | $208K | Buy |
5,660
+10
| +0.2% | +$389 | 0.06% | 158 |
|
|
2023
Q1 | $231K | Buy |
5,650
+197
| +4% | +$8.51K | 0.07% | 154 |
|
|
2022
Q4 | $279K | Buy |
5,453
+33
| +0.6% | +$1.58K | 0.09% | 136 |
|
|
2022
Q3 | $237K | Buy |
5,420
+7
| +0.1% | +$340 | 0.08% | 144 |
|
|
2022
Q2 | $284K | Buy |
5,413
+6
| +0.1% | +$306 | 0.09% | 135 |
|
|
2022
Q1 | $280K | Sell |
5,407
-1,093
| -17% | -$56.7K | 0.08% | 150 |
|
|
2021
Q4 | $384K | Sell |
6,500
-64
| -1% | -$3.17K | 0.11% | 137 |
|
|
2021
Q3 | $282K | Buy |
6,564
+3
| +0% | +$133 | 0.09% | 156 |
|
|
2021
Q2 | $257K | Buy |
6,561
+774
| +13% | +$30.1K | 0.08% | 156 |
|
|
2021
Q1 | $210K | Sell |
5,787
-1,032
| -15% | -$36.6K | 0.07% | 168 |
|
|
2020
Q4 | $251K | Sell |
6,819
-775
| -10% | -$28.4K | 0.09% | 150 |
|
|
2020
Q3 | $264K | Buy |
7,594
+334
| +5% | +$11.7K | 0.11% | 142 |
|
|
2020
Q2 | $225K | Buy |
7,260
+4
| +0.1% | +$136 | 0.07% | 172 |
|
|
2020
Q1 | $225K | Sell |
7,256
-36,128
| -83% | -$1.23M | 0.1% | 149 |
|
|
2019
Q4 | $1.61K | Buy |
43,384
+12,684
| +41% | +$452K | 0.65% | 41 |
|
|
2019
Q3 | $1.03M | Buy |
30,700
+1,677
| +6% | +$61K | 0.59% | 48 |
|
|
2019
Q2 | $1.19M | Buy |
29,023
+843
| +3% | +$33.5K | 0.72% | 40 |
|
|
2019
Q1 | $1.14M | Buy |
28,180
+3,614
| +15% | +$145K | 0.78% | 38 |
|
|
2018
Q4 | $1.02M | Buy |
+24,566
| New | +$1.02M | 0.9% | 35 |
|
Other funds holding PFE
Princeton Global Asset Management's PFE Position: Q2 2026 in Review
Princeton Global Asset Management reduced its Pfizer (PFE) stake by 4.4% in Q2 2026, selling an estimated $1.13K and leaving 933 shares worth $22.5K. The position accounts for ﹤0.01% of the portfolio, ranked #466.
Princeton Global Asset Management first reported a position in PFE in Q4 2018 and has held it in 31 quarters since. The position peaked at $1.19M in Q2 2019. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Princeton Global Asset Management held 933 shares of Pfizer worth $22.5K as of Q2 2026.
- Princeton Global Asset Management sold 43 Pfizer shares in Q2 2026, an estimated $1.13K.
- Pfizer made up ﹤0.01% of Princeton Global Asset Management's portfolio in Q2 2026, its #466 holding.
- Princeton Global Asset Management first reported a position in Pfizer in Q4 2018 and has held it in 31 quarters since.
- Princeton Global Asset Management's Pfizer position peaked at $1.19M in Q2 2019.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Princeton Global Asset Management's 13F filing for Q2 2026, filed 16 Jul 2026.